Aptahem (APTA) Q4 2024 earnings summary

Executive summary

• Revenue for Q4 2024 was 773 KSEK, down from 1,539 KSEK in Q4 2023; full-year revenue was 3,772 KSEK, down from 10,465 KSEK year-over-year.

• Net loss after financial items for Q4 was -2,881 KSEK (improved from -4,269 KSEK); full-year net loss was -8,568 KSEK (improved from -11,113 KSEK).

• Cash and cash equivalents at year-end were 4,132 KSEK, up from 2,091 KSEK.

• Solid equity ratio of 96.56% at year-end, up from 85.72% last year.

• Strategic partnership agreement signed with e-Projection in Japan to accelerate pharma and biotech collaborations.

Financial highlights

• Q4 operating income: 773 KSEK; full-year: 3,772 KSEK.

• Q4 net loss: -2,881 KSEK; full-year net loss: -8,568 KSEK.

• Q4 EPS: -0.23 SEK; full-year EPS: -0.69 SEK.

• Cash position at year-end: 4,132 KSEK.

• Development costs for Q4: 773 KSEK; full-year: 3,772 KSEK.

Outlook and guidance

• Planning for a phase 2 clinical study of Apta-1 in acute inflammatory conditions related to sepsis is ongoing, with focus on optimizing study design and patient population.

• Continued business development and partnership activities, especially in Japan and with global pharma/biotech companies.